Silodosin

Silodosin
Clinical data
Trade names	Urief, Rapaflo, Silodyx, others
Other names	KAD-3213, KMD-3213
AHFS/Drugs.com	Monograph
MedlinePlus	a609002
Routes of; administration	By mouth
Drug class	α1 blocker
ATC code	G04CA04 (WHO) ;
Legal status
Legal status	AU: S4 (Prescription only); CA: ℞-only; US: ℞-only; EU: Rx-only; In general: ℞ (Prescription only);
Pharmacokinetic data
Bioavailability	32%
Protein binding	96.6%
Metabolism	Liver glucuronidation (UGT2B7-mediated); also minor CYP3A4 involvement
Elimination half-life	13±8 hours
Excretion	33.5% Kidney, 54.9% fecal
Identifiers
	IUPAC name 1-(3-hydroxypropyl)-5-[(2R)-({2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]indoline-7-carboxamide;
CAS Number	160970-54-7 ;
PubChem CID	5312125;
IUPHAR/BPS	493;
DrugBank	DB06207 ;
ChemSpider	4471557 ;
UNII	CUZ39LUY82;
KEGG	D01965;
ChEMBL	ChEMBL24778 ;
CompTox Dashboard (EPA)	DTXSID40167045 ;
ECHA InfoCard	100.248.664
Chemical and physical data
Formula	C25H32F3N3O4
Molar mass	495.543 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC(F)(F)COc3ccccc3OCCN[C@H](C)Cc1cc2c(c(c1)C(=O)N)N(CC2)CCCO;
	InChI InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1 ; Key:PNCPYILNMDWPEY-QGZVFWFLSA-N ;
	(what is this?) (verify)

Silodosin, sold under the brand name Urief among others, is a medication used for the symptomatic treatment of benign prostatic hyperplasia. It acts as an alpha-1 adrenergic receptor antagonist.

The most common side effect is a reduction in the amount of semen released during ejaculation.